gastric cancer is a highly aggressive malignancy with a poor overall outcome. The purpose of this study is to evaluate the 5-year survival of neoadjuvant S1, oxaliplatin, and docetaxel (SLOT) versus S1, oxaliplatin(SOX) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer.

Two arms, phase 3 study of neoadjuvant S1, oxaliplatin, and docetaxel (SLOT) versus S1, oxaliplatin(SOX) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer. 380 Patients will be enrolled in this trial. The primary objective of this study is to determine the 5-year survival of the two arms.

Inclusion Criteria:

• Histologically proven gastric or GE junction adenocarcinoma;
• Age: 18 to 70;
• ECOG 0-2;
• Adenocarcinoma of the stomach or GE junction according to staging classification TNM Scannographic: T3-4 N0/N + M0 ;
• Completion of baseline quality of life questionnaire
• Adequate bone marrow functions (ANC ≥ 1,500/ul, blood platelet ≥ 100,000/ul, haemoglobin ≥ 10g/dl);
• Adequate renal functions(serum creatinine ≤ 1.5mg/dl)
• liver functions (serum bilirubin ≤ 1.5UNL, AST/ALT ≤ 3 times(normal value)
• Written informed consent

Exclusion Criteria:

• Previous chemotherapy;
• Active infection requiring antibiotics
• Pregnant, lactating women
• Psychiatric illness, epileptic disorders
• Concurrent systemic illness not appropriate for chemotherapy
• History of other malignancy within 5 years except for non-melanoma skin cancer, cervix in situ carcinoma